Additional Coverage:
- FDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades (cnbc.com)
New Schizophrenia Drug Approved by FDA
The Food and Drug Administration (FDA) has approved Cobenfy, a novel drug for schizophrenia. This is the first new treatment for this chronic condition in over 70 years.
Availability and Pricing
Cobenfy, a twice-daily pill, is expected to be available in late October. It will cost $1,850 per month, or $22,500 annually, before insurance. Bristol Myers Squibb, the drug’s manufacturer, plans to offer assistance programs to help patients afford the medication.
Benefits and Side Effects
Cobenfy works differently from existing schizophrenia medications, which can cause serious side effects. It aims to reduce symptoms without triggering these side effects, such as weight gain and involuntary movements.
Target Population
Nearly 3 million adults in the US live with schizophrenia, but only half receive treatment. Cobenfy is intended for those who have struggled to find effective or tolerable existing medications.
Potential Impact
Experts believe Cobenfy could become a standard treatment for schizophrenia. However, its high cost may limit its use to those who have already tried and failed other medications.
Ongoing Research
Bristol Myers Squibb is exploring Cobenfy’s potential for treating Alzheimer’s disease, bipolar mania, and autism-related irritability. Clinical trials are underway, with data expected in the coming years.